Please Wait
Applying Filters...
Menu
Xls
Filters Filter
Cross PopUp
FILTER :

filter clear-filterReset all filters

01 6Yescarta

PharmaCompass

01

Brand Name : Yescarta

Axicabtagene Ciloleucel

arrow
Fi Europe 2024
Not Confirmed

Brand Name : Yescarta

arrow
Fi Europe 2024
Not Confirmed

Axicabtagene Ciloleucel

Main Therapeutic Indication : Oncology

Currency : USD

2020 Revenue in Millions : 563

2019 Revenue in Millions : 456

Growth (%) : 23

blank

02

Brand Name : Yescarta

Axicabtagene Ciloleucel

arrow
Fi Europe 2024
Not Confirmed

Brand Name : Yescarta

arrow
Fi Europe 2024
Not Confirmed

Axicabtagene Ciloleucel

Main Therapeutic Indication : Oncology

Currency : USD

2021 Revenue in Millions : 695

2020 Revenue in Millions : 563

Growth (%) : 23

blank

03

Brand Name : Yescarta

Axicabtagene Ciloleucel

arrow
Fi Europe 2024
Not Confirmed

Brand Name : Yescarta

arrow
Fi Europe 2024
Not Confirmed

Axicabtagene Ciloleucel

Main Therapeutic Indication : Oncology

Currency : USD

2022 Revenue in Millions : 1,160

2021 Revenue in Millions : 695

Growth (%) : 67

blank

04

Brand Name : Yescarta

Axicabtagene Ciloleucel

arrow
Fi Europe 2024
Not Confirmed

Brand Name : Yescarta

arrow
Fi Europe 2024
Not Confirmed

Axicabtagene Ciloleucel

Main Therapeutic Indication : Oncology

Currency : USD

2023 Revenue in Millions : 1,498

2022 Revenue in Millions : 1,160

Growth (%) : 29

blank

05

Brand Name : Yescarta

Axicabtagene Ciloleucel

arrow
Fi Europe 2024
Not Confirmed

Brand Name : Yescarta

arrow
Fi Europe 2024
Not Confirmed

Axicabtagene Ciloleucel

Main Therapeutic Indication : Oncology

Currency : USD

2018 Revenue in Millions : 264

2017 Revenue in Millions : 7

Growth (%) : 3671%

blank

06

Brand Name : Yescarta

Axicabtagene Ciloleucel

arrow
Fi Europe 2024
Not Confirmed

Brand Name : Yescarta

arrow
Fi Europe 2024
Not Confirmed

Axicabtagene Ciloleucel

Main Therapeutic Indication : Oncology

Currency : USD

2019 Revenue in Millions : 456

2018 Revenue in Millions : 264

Growth (%) : 73

blank